Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$10.98 +0.14 (+1.29%)
As of 10:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Key Stats

Today's Range
$10.64
$11.12
50-Day Range
$6.07
$10.84
52-Week Range
$5.14
$29.46
Volume
31,253 shs
Average Volume
333,528 shs
Market Capitalization
$590.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Buy

Company Overview

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Upstream Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

UPB MarketRank™: 

Upstream Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 623rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Upstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Upstream Bio has received no research coverage in the past 90 days.

  • Read more about Upstream Bio's stock forecast and price target.
  • Short Interest

    There is no current short interest data available for UPB.
  • Dividend Yield

    Upstream Bio does not currently pay a dividend.

  • Dividend Growth

    Upstream Bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for UPB.
  • News Sentiment

    Upstream Bio has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Upstream Bio this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Upstream Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Upstream Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.56% of the stock of Upstream Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Upstream Bio's insider trading history.
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

UPB Stock News Headlines

When This Happens, You Don’t Wait. You Act.
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Upstream Bio Appoints Stacy Price As CTO
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $16.44 at the start of the year. Since then, UPB shares have decreased by 34.1% and is now trading at $10.84.
View the best growth stocks for 2025 here
.

Upstream Bio, Inc. (NASDAQ:UPB) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million.

Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

Upstream Bio's lock-up period expired on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

Top institutional investors of Upstream Bio include Wellington Management Group LLP (2.44%), Siren L.L.C. (1.47%), Siren L.L.C. (1.47%) and Nantahala Capital Management LLC (1.11%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc.
View institutional ownership trends
.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/06/2025
Today
6/04/2025
Next Earnings (Estimated)
6/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.50
High Stock Price Target
$75.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+421.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.30 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$583.13 million
Optionable
N/A
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 6/4/2025 by MarketBeat.com Staff
From Our Partners